“…Evidence of activity of anti-EGFR agents in advanced penile cancer was originally reported when administered as single agent (Necchi et al, 2016b) or in combination with chemotherapy (Rescigno et al, 2012). In a literature review of individual data of 28 patients with advanced penile cancer receiving anti-EGFR monoclonal antibodies (cetuximab, panitumumab, and nimotuzumab), a 50% radiological response rate was achieved, but a median PFS of only approximately 3 months (interquartile range, 1.5–5.78, Di Lorenzo et al, 2015). From a biological perspective, EGFR appears a promising target in penile cancer, as it is universally expressed and frequently phosphorylated (Di Lorenzo et al, 2013a), but infrequently amplified (Di Lorenzo et al, 2013a), or mutated (Di Lorenzo et al, 2013b), while mutations of downstream signaling proteins (such as KRAS/BRAF) are rare (Gou et al, 2013).…”